DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: aminolevulinic acid hydrochloride

Summary for Generic Name: aminolevulinic acid hydrochloride

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list6
Suppliers: see list1

Clinical Trials for: aminolevulinic acid hydrochloride

The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
Status: Not yet recruiting Condition: Central Nervous System Tumor, Pediatric

Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood
Status: Completed Condition: Insomnia; Nocturnal Awakening; Irritability; Coping Behavior; Stress

A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Status: Withdrawn Condition: Brain Neoplasms

Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
Status: Terminated Condition: Oral Leukoplakia

Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Status: Terminated Condition: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor

Fluorescence-guided Surgery for Low- and High-grade Gliomas
Status: Recruiting Condition: Glioma

Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Status: Active, not recruiting Condition: Glioblastoma

Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery
Status: Not yet recruiting Condition: Primary Malignant Neoplasm of Nervous System; Glioma; Glioblastoma; Metastasis

5-ALA in Recurrent Glioma
Status: Recruiting Condition: Recurrent Glioma

Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
Status: Not yet recruiting Condition: Basal Cell Nevus Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965Dec 3, 1999RXYes5,079,262<disabled>TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965Dec 3, 1999RXYes5,954,703<disabled>TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965Dec 3, 1999RXYes6,709,446<disabled>TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965Dec 3, 1999RXYes7,723,910<disabled>TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc